Here is an interesting new therapy being developed – it uses blue light to produce cyclic guanosine monophosphate (cGMP), a chemical that contributes to erections.
Here is an article on this, from this link: ARTICLE
BLUE LIGHT TO TREAT ERECTILE DYSFUNCTION
From the age of 30, the number of men who have unsatisfactory erections or none at all increases. In the over-60 age group, more than half of all men have been affected by erectile dysfunction, a disorder in which normal sexual stimulation does not lead to an erection.
The main causes include cardiovascular disease, diabetes, hormonal imbalance, neurological disease, and the side effects of medication. Even spinal paralysis can result in patients no longer being able to have erections.
A gene construct that reacts to blue light is injected into the erectile tissue of the penis. As soon as it is exposed to the light, a precursor molecule (guanosine triphosphate or GTP) is converted into the second messenger cyclic guanosine monophosphate (cGMP), which exists naturally in a number of human organs.
This allows voltage-dependent calcium channels to close, thereby reducing calcium levels in the cells, which in turn relaxes muscle cells and increases blood flow to the erectile tissue. And so the penis becomes stiff.
An enzyme then slowly breaks down cGMP so that the erection wears off with time. Viagra blocks this enzyme and intensifies and prolongs the erection, but it cannot trigger one.
Thanks to the gene construct, the production of cGMP is not stimulated by sexual arousal but by exposure of the erectile tissue to blue light.
“In this way, we circumvent the usual sexual stimulation that triggers a cascade of signals in the body and ultimately leads to an erection,” says study leader Martin Fussenegger, professor of biotechnology and bioengineering at ETH Zurich in Basel.
The researchers tested their new development in male rats by injecting the gene construct into the erectile tissue—with good results. Their findings appear in Angewandte Chemie.
In most cases, the blue light acted like a switch that allowed the rats’ erection to be “turned on.” For some of the animals, the stimulation even led to ejaculation.
“The system of an erection is very similar across all mammals,” says Fussenegger. He is therefore convinced that the gene construct will also work in humans. “Even Viagra works on rats. It prolongs the erection’s intensity, just as it does in humans.”
“Injection of a gene construct should not be a barrier to potential users, as injections in the erectile tissue are already a standard treatment for erectile dysfunction these days,” says Fussenegger.
The erectile tissue is largely insensitive to pain; it is also for the most part detached from normal blood circulation, so the probability that the gene construct could reach other parts of the body is very low.
In addition, cGMP breaks down relatively quickly. As Viagra prolongs the erection, any possible gene therapy could be supplemented by this medication.
An artificially induced erection would satisfy a great need among patients suffering from erectile dysfunction, says Fussenegger. “Several doctors have confirmed this to me,” he says. In addition, not all sufferers are allowed to take Viagra, such as those with known heart disease.
Researchers worked on this gene construct for four years and for the time being it exists only as a prototype; tests in humans have yet to take place. “Before it can be used as a treatment, it requires highly expensive clinical tests,” says Fussenegger. “We are actively looking for partners to put our technology into clinical practice.”